Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Sanguine Biosciences

Status: Enrolling

Conditions: Age-Related Macular Degeneration; Celiac Disease; Vitiligo; Hepatitis; Pemphigus Vulgaris; Amyloidosis; Sickle Cell Disease; Graves Disease; Cancer; Alopecia Areata; Allergies; Alpha-Gal Syndrome; Diabetes; Schizophrenia; Multiple Sclerosis; Scleroderma; Parkinson Disease; Lymphoma; Cystic Fibrosis; COPD; Heart Diseases; Crohn Disease; Ankylosing Spondylitis; Lupus or SLE; Thyroid Diseases; DMD; Psoriasis; ALS; ITP; Fibromyalgia; Autoimmune Hepatitis; Stroke; Cirrhosis; Leukemia; Hidradenitis Suppurativa; Autism; Atopic Dermatitis; Myasthenia Gravis; Asthma; Alzheimer Disease; Kidney Diseases; Beta-Thalassemia; Arthritis; Vasculitis; Ulcerative Colitis; Dravet Syndrome; Behcet's Disease

Treatments: Diagnostic Test: Specimen sample

Study type: Observational

Funder types: Industry

Identifiers

NCT05635266

SAN-BB-02

Details and patient eligibility

About

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.

Enrollment: 20,000 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Persons 18 to 85 years of age at the date of informed consent.
• If presenting with a history of a specific condition, the diagnosis is confirmable in the medical record or may be confirmed using other forms of verification including self-reporting.
• Understands the procedures and requirements of the study by providing written informed consent (or verbal assent if a legally authorized representative will sign the ICF), including consent for authorization for protected health information disclosure.

Exclusion criteria

• Persons younger than 18 years of age or older than 85 years of age at the date of informed consent.
• Receipt of blood products 30 days before the study blood draw.
• Receipt of an investigational (unapproved) drug 30 days before the study blood draw.
• A confirmable diagnosis of any medical condition that would increase potential phlebotomy risks.
• Has donated a unit of blood within the last 2 months at the date of informed consent.

Trial design

20,000 participants in 3 patient groups

Health Condition Group

Treatment:

Diagnostic Test: Specimen sample

Exceptive Condition Group

Treatment:

Diagnostic Test: Specimen sample

Control Group

Treatment:

Diagnostic Test: Specimen sample